# A Study Of PF-06664178 In Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct02122146/  
OnCo record `nct02122146` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This study tests TROP-2-directed treatment; the registry reports that it is terminated.

## Summary

The registry lists NCT02122146 as terminated, last updated 2018-02-19. Enrolment is 31 actual participants. Interventions: PF-06664178. Primary measures include First Cycle Dose Limiting Toxicities (DLTs) In Order to Determine the Maximum Tolerated Dose(MTD); Number of Patients With All-Causality Treatment-Emergent Adverse Events(TEAEs) [Part 2 & 3]. The registry reason for stopping is: The study was prematurely discontinued due to a business-related decision on 09-FEB-2016. The decision to terminate the trial was based on the overall results. Results are posted in the registry.

## Fields

- Kind: Trial
- Status: withdrawn
- Last checked: 2026-10-06
- Registry id: NCT02122146
- Phase: 1
- Setting: A Phase 1, Dose Escalation Study Of Pf-06664178 In Patients With Locally Advanced Or Metastatic Solid Tumors
- Sponsor: Pfizer
- Enrolled: 31

## Sources

- ClinicalTrials.gov NCT02122146: https://clinicaltrials.gov/study/NCT02122146

## Connected records

- targets: [TROP2](https://onco.cc/targets/trop2/)
- drugs: [PF-06664178](https://onco.cc/drugs/pf-06664178/)

---
JSON: https://onco.cc/api/v1/entities/nct02122146.json